Immunotherapy, such as programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint inhibitors and CTLA4, concentrates on revitalizing immunologic cells to release molecular components to defend against cancer cell in the tumor microenvironment. Here, PDCD1 is linked to neoplasm.